source
- STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatmentPfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.
- U.S. 'most-favored nations' policy prompts drugmakers to reconsider overseas launchesThe White House's "most-favored nations" rule, which would tie foreign drug prices to U.S. prices, is causing U.S. pharma firms to rethink launching products abroad. Companies are exploring strate…